Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

Leukemia

Volumn 20, Issue 6, 2006, Pages 952-957

  Roboz, G J ^a   Giles, F J ^b   List, A F ^c   Cortes, J E ^b   Carlin, R ^a   Kowalski, M ^d   Bilic, S ^d   Masson, E ^d   Rosamilia, M ^d   Schuster, M W ^a   Laurent, D ^e   Feldman, E J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e BAYER PHARMA AG   (Germany)

Author keywords

Myelodysplastic syndrome; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTARABINE; DAUNORUBICIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERUCTATION; FATIGUE; FEMALE; HICCUP; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LETHARGY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; PERIPHERAL CIRCULATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PRURITUS; STEADY STATE; THROMBOCYTOPENIA; WEAKNESS;

EID: 33744482540     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404213     Document Type: Article

References (27)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995; 1: 27-31.
2. Weinstat-Saslow D, Steeg PS. Angiogenesis and colonization in the tumor metastatic process: Basic and applied advances. FASEB J 1994; 8: 401-407.
3. Liotta LA, Steep PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of negative and positive regulation. Cell 1991; 64: 327-336.
4. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 96: 2637-2644.
5. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-313.
6. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
7. De Bont ED, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukemia: A possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296-304.
8. Dvorak HF, Detmar M, Clafey KP. Vascular permeability factor (vascular endothelial growth factor) - an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995; 107: 233-235.
9. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127-137.
10. Zhang HT, Craft P, Scott PAE. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor in MCF-7 human breast carcinoma cells. J Nat Cancer Inst 1995; 87: 213-219.
11. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML et al. Failure of blood-island formation and vasculogenesis in FLK-1 deficient mice. Nature 1995; 376: 62-66.
12. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439.
13. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
14. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398-1401.
15. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870-1875.
16. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434.
17. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
18. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857-10862.
19. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717-3721.
20. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
21. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002; 92: 4015-4122.
22. Morgan B, Thomas AL, Devs J, Hennig J, Buchert M, Jivan A et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
23. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of the international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
24. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005; 23: 4162-4171.
25. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges and open questions. J Clin Oncol 2005; 23: 1295-1311.
26. Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241-243.
27. Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10: 3577-3585.